Bank Of America Corp Contrafect Corp Transaction History

Bank Of America Corp

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 10, 2023	SELL	$0.09 - $0.19 $25 - $54	-288 Reduced 36.55%	500 $0
Q2 2022 Aug 12, 2022	SELL	$2.79 - $4.45 $225 - $360	-81 Reduced 9.32%	788 $2,000
Q1 2022 May 16, 2022	SELL	$2.26 - $3.84 $1,900 - $3,229	-841 Reduced 49.18%	869 $3,000
Q4 2021 Feb 08, 2022	SELL	$2.47 - $4.14 $12,935 - $21,681	-5,237 Reduced 75.39%	1,710 $4,000
Q3 2021 Nov 15, 2021	SELL	$3.19 - $4.43 $46,908 - $65,143	-14,705 Reduced 67.92%	6,947 $28,000
Q2 2021 Sep 13, 2021	BUY	$3.58 - $4.9 $77,514 - $106,094	21,652 New	21,652 $95,000

49.2K

Ticker CFRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,332,700
Market Cap $1.18M
Description
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus...

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

Stay updated on Bank Of America Corp with notifications on news.